Phase II trial of AN363 for the treatment of neuropathic pain

Trial Profile

Phase II trial of AN363 for the treatment of neuropathic pain

Suspended
Phase of Trial: Phase II

Latest Information Update: 09 May 2016

At a glance

  • Drugs AN 363 (Primary)
  • Indications Neuropathic pain
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Saniona
  • Most Recent Events

    • 09 May 2016 Status changed from planning to suspended, according to a Saniona media release.
    • 09 May 2016 According to a Saniona media release, the company announced that the ongoing investigations on the AN363 compound will be put on hold.
    • 14 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top